Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future-Reference-Cited by-同舟云学术

Gemtuzumab ozogamicin in acute myeloid leukemia: past, present and future

Published:2020-11 Issue:5 Volume:111 Page:
ISSN:0026-4806
Container-title:Minerva Medica
language:
Short-container-title:Minerva Med

Author:

Gottardi Michele,Sperotto Alessandra,Ghelli Luserna Di Rorà Andrea,Padella Antonella,Cangini Delia,Giannini Maria B.,Simonetti Giorgia,Martinelli Giovanni,Cerchione Claudio

Publisher

Edizioni Minerva Medica

Subject

General Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R10Y2020N05A0395

Reference89 articles.

1. The L4F3 antigen is expressed by unipotent and multipotent colony- forming cells but not by their precursors

2. Acute myeloid leukemia stem cells and CD33-targeted immunotherapy

3. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia

4. Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML

5. CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell–engaging antibody AMG 330

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement;Drug Resistance Updates;2024-07

2. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers;Molecular Cancer;2024-03-23

3. Gemtuzumab Ozogamicin in Acute Myeloid Leukemia: Efficacy, Toxicity, and Resistance Mechanisms—A Systematic Review;Biomedicines;2024-01-17

4. Antibody therapies for the treatment of acute myeloid leukemia: exploring current and emerging therapeutic targets;Expert Opinion on Investigational Drugs;2023-02-01

5. No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group;Disease Markers;2022-08-23